Cormorant Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-125,000
| Closed | -$9.97M | – | 53 |
|
|
2017
Q2 | $9.97M | Buy |
+125,000
| New | +$9.97M | 1.65% | 21 |
|
|
2016
Q4 | – | Sell |
-126,120
| Closed | -$8.55M | – | 79 |
|
|
2016
Q3 | $8.55M | Sell |
126,120
-74,235
| -37% | -$5.03M | 0.94% | 35 |
|
|
2016
Q2 | $11.1M | Sell |
200,355
-44,645
| -18% | -$2.48M | 1.58% | 24 |
|
|
2016
Q1 | $15.4M | Hold |
245,000
| – | – | 2.32% | 12 |
|
|
2015
Q4 | $23.1M | Buy |
245,000
+105,000
| +75% | +$9.88M | 2.76% | 11 |
|
|
2015
Q3 | $11.3M | Hold |
140,000
| – | – | 1.8% | 19 |
|
|
2015
Q2 | $16.8M | Buy |
+140,000
| New | +$16.8M | 2.23% | 13 |
|
|
2014
Q4 | – | Sell |
-50,000
| Closed | -$3.91M | – | 71 |
|
|
2014
Q3 | $3.91M | Hold |
50,000
| – | – | 0.8% | 34 |
|
|
2014
Q2 | $3.16M | Hold |
50,000
| – | – | 0.84% | 40 |
|
|
2014
Q1 | $3.36M | Sell |
50,000
-200,000
| -80% | -$13.4M | 0.77% | 37 |
|
|
2013
Q4 | $16.1M | Buy |
+250,000
| New | +$16.1M | 4.67% | 10 |
|